leadf
logo-loader
viewArecor

Arecor CEO updates as data for lead insulin product is presented at American Diabetes Association

Arecor Limited's Sarah Howell speaks to Proactive's Andrew Scott after the company presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, to the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting.

AT247 has been formulated to accelerate insulin absorption, post-injection, to enable more effective management of blood glucose levels.

Howell says the next step will be to explore AT247’s potential as the ideal insulin for use in a pump and fully closed-loop delivery (artificial pancreas) systems.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

on 10/20/2020

2 min read